Suppr超能文献

5q 缺失的骨髓增生异常综合征和急性髓系白血病中 17p 缺失和 TP53 突变的发生率。

Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.

机构信息

Laboratoire d'Hématologie, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP)/Université Paris 13, Bobigny. France.

出版信息

Genes Chromosomes Cancer. 2012 Dec;51(12):1086-92. doi: 10.1002/gcc.21993. Epub 2012 Aug 30.

Abstract

TP53 mutations are frequent in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with complex karyotype that include del(5q) and are often associated with deletion of 17p. They have also recently been observed in MDS with isolated del(5q). We assessed the incidence of 17p deletion detected by fluorescence in situ hybridization (FISH) and of TP53 mutations detected by direct sequencing and their correlation and prognostic value in 26 MDS and 17 AML with del(5q). In the 20 cases with isolated del(5q) or one additional abnormality, no 17p deletion was found and 3 of the 18 cases analyzed (17%) had TP53 mutation. In the 23 patients with complex karyotype, 17p deletion was suspected by conventional cytogenetics in 15 cases and confirmed by FISH in 10 of them, while TP53 mutation was found in 8 of the 15 patients tested (53%), only five of whom had 17p deletion. In the whole patient series, TP53 mutations were associated with shorter survival (P = 0.07). We confirm the existence of TP53 mutations in 17% of MDS with isolated del(5q). In patients with del(5q) and complex karyotype, FISH and direct sequencing are complementary techniques to analyze TP53 abnormalities. Our findings also suggest that sequencing of the TP53 gene should be included in the study of patients with del(5q) as a single abnormality or in complex karyotype before lenalidomide treatment.

摘要

TP53 基因突变在伴复杂核型的骨髓增生异常综合征(MDS)和急性髓系白血病(AML)中很常见,这些核型包括 del(5q),并且常伴有 17p 缺失。最近也在孤立性 del(5q)的 MDS 中观察到了这种基因突变。我们评估了通过荧光原位杂交(FISH)检测到的 17p 缺失、通过直接测序检测到的 TP53 突变的发生率,以及它们在 26 例伴 del(5q)的 MDS 和 17 例 AML 中的相关性和预后价值。在 20 例孤立性 del(5q)或 1 种额外异常的病例中,未发现 17p 缺失,而在分析的 18 例病例中,有 3 例(17%)存在 TP53 突变。在 23 例复杂核型患者中,15 例通过常规细胞遗传学怀疑存在 17p 缺失,其中 10 例通过 FISH 得到证实,而在 15 例检测的患者中有 8 例(53%)发现 TP53 突变,其中只有 5 例存在 17p 缺失。在整个患者系列中,TP53 突变与较短的生存期相关(P = 0.07)。我们确认在 17%的孤立性 del(5q)的 MDS 中存在 TP53 突变。在伴有 del(5q)和复杂核型的患者中,FISH 和直接测序是分析 TP53 异常的互补技术。我们的研究结果还表明,在 lenalidomide 治疗前,对于仅有 del(5q)单一异常或复杂核型的患者,应将 TP53 基因测序纳入研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验